Sangamo Therapeutics, the 30-year-old gene-editing pioneer, filed for Chapter 11 bankruptcy with Eli Lilly and Astellas Pharma acquiring its assets. The zinc finger nuclease developer's collapse demonstrates how technological disruption and market dynamics can overtake foundational innovators, with CRISPR's emergence and manufacturing challenges undermining Sangamo's competitive edge. The asset consolidation reflects the biotech sector's ongoing challenge in converting early-stage research advantages into sustainable commercial success.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





